

**APPROVED**

**By Jean Gildner at 2:52 pm, Jul 19, 2016**

**From:** Gildner, Jean  
**To:** [maquilera@vcel.com](mailto:maquilera@vcel.com)  
**Bcc:** [Kenney, James](#); [Thomas, John](#)  
**Subject:** BLA125603 IR regarding (b) (4) Validation  
**Date:** Wednesday, June 29, 2016 2:23:00 PM  
**Attachments:** [201606229\\_STN 125603 2ed Information Request for \(b\) \(4\) \\_method.doc](#)

---

Dear Margarita,

Please find attached the IR regarding the (b) (4) discussed by Dr. Kenney today at our tcon. If you have any additional questions please feel free to contact me. Please acknowledge receipt of this email.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP), CQA (ASQ)

Regulatory Project Manager

FDA/CBER/OCTGT

10903 New Hampshire Avenue

Bldg. 71, RM. 5222

Silver Spring, MD 20993-0002

Phone: (240) 402-8296

Fax: (301) 595-1303

[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.